title: Bedaquiline and delamanid in tuberculosis.
abstract: BACKGROUND
  In recent years, a pressing need to develop new, effective and safe drugs against tuberculosis (TB) has continued. Poor adherence to a long therapeutic regimen against TB, intermittent drug use, errors in medical prescriptions, low quality of old TB drugs and ineffective TB control have led to the emergence of resistant TB.
  
  
  METHODS
  Two new drugs have gained importance and seem promising against resistant TB: bedaquiline and delamanid. This review summarizes the main characteristics of these two drugs and their role in TB management.
  
  
  CONCLUSIONS
  Bedaquiline and delamanid appear to be promising new anti-TB drugs. Due to a mechanism of action that is different from that of other available drugs, their efficacy has appeared optimal in cases of adults with resistant pulmonary TB. Although their pharmacokinetic and pharmacodynamic profiles seem optimal, potential cardiologic side effects such as QT-interval prolongation have been associated with their use. However, specific studies performed in the pediatric population are needed to confirm these results. This seems particularly important considering the long duration of TB treatment required for resistant TB as well as the potential interactions with other drugs included in anti-TB regimens or administered for an underlying comorbidity.
authors: a 1 Università degli Studi di Milano, Pediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , Milan, Italy +39 02 55 03 24 98 ; +39 02 50 32 02 06 ; susanna.esposito@unimi.it.
authors: Susanna
authors: S
authors: Esposito
authors: a 1 Università degli Studi di Milano, Pediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , Milan, Italy +39 02 55 03 24 98 ; +39 02 50 32 02 06 ; susanna.esposito@unimi.it.
authors: Sonia
authors: S
authors: Bianchini
authors: b 2 Università degli Studi di Milano, Pneumology Unit, Department of Pathophysiology and Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , Milan, Italy.
authors: Francesco
authors: F
authors: Blasi
mesh_terms: D000995:Antitubercular Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D064687:Diarylquinolines / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D004347:Drug Interactions; D024881:Drug Resistance, Bacterial; D006801:Humans; D009593:Nitroimidazoles / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D010080:Oxazoles / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D064687:Diarylquinolines; D009593:Nitroimidazoles; C516022:OPC-67683; D010080:Oxazoles; C493870:bedaquiline
keywords: bedaquiline; children; delamanid; extensively drug-resistant tuberculosis; multidrug-resistant tuberculosis; pediatric tuberculosis; tuberculosis